Baxter sees some recessionary risk in 2023

Says hospital capital environment in 2023 an "important variable" for the company. Says dimensions "somewhat limited" as far as company’s ability to raise prices until contracts expire at the end of 2024. Says can’t raise prices to offset higher costs until end of 2024. Says close to being in position to submit new pump to FDA, which is an "important variable" for 2023. Comments taken from Evercore ISI Healthconx Conference.